Clinicopathologic characteristics of the study population and analyses of factors that predicted disease progression, PCSM, and ACM during ADT.

Abbreviations: ADT, androgen-deprivation therapy; PCSM, prostate cancer-specific mortality; ACM, all-cause mortality; PSA, prostate-specific antigen; IQR, interquartile range; RP, radical prostatectomy; RT, radiotherapy.*Column subtotals do not sum to 645 for no. of patients, 444 for no. of disease progression, 114 for PCSM, and 162 for ACM due to missing data.†P values were calculated using the log-rank test.P≤0.05 are in boldface.